Stocks & Investing
Wed, September 4, 2024
[ 12:00 AM ] - WOPRAI
Mon, May 13, 2024
[ 12:00 AM ] - WOPRAI
Wed, April 17, 2024
[ 12:00 AM ] - WOPRAI
Mon, November 13, 2023
[ 12:00 AM ] - WOPRAI
Thu, November 9, 2023
Tue, October 10, 2023
[ 12:00 AM ] - WOPRAI
Tue, September 26, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 8, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 18, 2023
[ 12:00 AM ] - WOPRAI
Mon, May 8, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 4, 2023
[ 12:00 AM ] - WOPRAI
Fri, March 31, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 21, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
Tue, February 28, 2023
[ 12:00 AM ] - WOPRAI
Thu, February 16, 2023
[ 12:00 AM ] - WOPRAI
Thu, October 6, 2022
[ 12:00 AM ] - WOPRAI
Thu, May 5, 2022
[ 12:00 AM ] - WOPRAI
Mon, April 25, 2022
[ 12:00 AM ] - WOPRAI
Wed, March 2, 2022
[ 12:00 AM ] - WOPRAI
Fri, January 7, 2022
[ 12:00 AM ] - WOPRAI
Tue, October 7, 2014 Mason Carrico Reiterated (TXG) at Buy and Held Target at $30 on, Sep 4th, 2024
Mason Carrico of Stephens & Co., Reiterated "10x Genomics, Inc." (TXG) at Buy and Held Target at $30 on, Sep 4th, 2024.
Mason has made no other calls on TXG in the last 4 months.
There are 13 other peers that have a rating on TXG. Out of the 13 peers that are also analyzing TXG, 6 agree with Mason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Dan Leonard of "UBS" Maintained at Hold with Decreased Target to $25 on, Tuesday, August 13th, 2024
- Rachel Vatnsdal of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $20 on, Thursday, July 18th, 2024
- Derik De Bruin of "B of A Securities" Maintained at Hold with Decreased Target to $25 on, Thursday, July 18th, 2024
- Justin Bowers of "Deutsche Bank" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Wednesday, July 10th, 2024
- Doug Schenkel of "Wolfe Research" Downgraded from Buy to Hold on, Thursday, June 27th, 2024
- Subbu Nambi of "Guggenheim" Downgraded from Strong Buy to Hold on, Wednesday, June 26th, 2024
These are the ratings of the 7 analyists that currently disagree with Mason
- Mike Kratky of "Leerink Partners" Initiated at Buy and Held Target at $35 on, Tuesday, September 3rd, 2024
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $46 on, Tuesday, August 13th, 2024
- Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $32 on, Tuesday, July 23rd, 2024
- Tycho Peterson of "Jefferies" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, July 22nd, 2024
- Daniel Arias of "Stifel" Maintained at Strong Buy with Decreased Target to $25 on, Tuesday, July 16th, 2024
- Matthew Sykes of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $16 on, Tuesday, July 9th, 2024
- Luke Sergott of "Barclays" Maintained at Buy with Decreased Target to $24 on, Friday, June 28th, 2024
